
Cytomegalovirus Retinitis Market Comprehensive Review of its Applications Growth Opportunities and Future Prospects
Pramod KmrFebruary 15, 2019analysis, Cytomegalovirus Retinitis Market, Cytomegalovirus Retinitis Market Demand, Cytomegalovirus Retinitis Market Share, Cytomegalovirus Retinitis Market Size, Growth, Outlook, Trends
No comments
One of the
major trends noticed in the cytomegalovirus retinitis market is usage of
off-label drugs for the treatment of cytomegalovirus retinitis. Innovation of
products focusing on better efficacy, growing demographics and growing
economies in the developing countries, such as China and India, are some of the
opportunities for global cytomegalovirus retinitis market.

Cytomegalovirus
retinitis is eye disease caused due to retina inflammation of eye. The
causative agent of the disease is cytomegalovirus, a herpes virus that affects
the photosensitive cells of retina. After affecting the retina, the disease
spreads from one eye to another eye, which can lead to blindness, if left
untreated. Photophobia, blurred vision, seeing floaters and blind spots are the
symptoms of cytomegalovirus retinitis. Cytomegalovirus retinitis usually
affects people with weak immune system, including HIV affected patients.
Various forms of cytomegalovirus retinitis medication are solutions, capsules,
tablets and implants.
Request to Get the
Sample Pages at:
Some of the
major factors restraining the growth of the global cytomegalovirus retinitis
market are lack of awareness among people for different types of eye diseases,
rising healthcare cost in developing countries and lack of healthcare
insurance. Majority of the population do not have proper access to primary
healthcare services because of poverty and absence of health insurance, which
is also hindering the growth of cytomegalovirus retinitis market. The other
major challenge for the global cytomegalovirus retinitis market is lack of
approved treatment guidelines by the World Health Organization (WHO).
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cytomegalovirus-retinitis-market
North
America has the largest market for cytomegalovirus retinitis due to improved
medical facilities and increasing occurrence of cytomegalovirus retinitis cases
in the region. Asia-Pacific is growing with the highest rate among global
cytomegalovirus retinitis market. In Asia-Pacific, China and India are the two
fastest growing cytomegalovirus retinitis markets, attributed to raising
government initiatives and support and large population in these countries.
Some of the
major competitors of global
cytomegalovirus retinitis market are, Shire Plc, F. Hoffmann-La Roche
AG, Hospira Inc., Chimerix Inc., Gilead Sciences Inc., pSivida, Auritec
Pharmaceuticals Inc., Sanofi S.A., and Isis Pharmaceuticals Inc.
Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Analysis by Stages, Drug Class, Company Profile, Phase of Development, and Discovery Stage Insights
Pramod KmrFebruary 12, 2019Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Size, Demand, Growth, Outlook, Research Report, Share
No comments
The global
chronic lymphocytic leukemia therapeutics market is expected to create more
opportunities in oncology due to promising pipeline and positive clinical data
of drug candidates. The existing drugs for the treatment of chronic lymphocytic
leukemia is the be most effective treatment. The American Cancer Society, and
other regulatory bodies are supporting the chronic lymphocytic leukemia therapeutics
market by providing funding and grants. The market is being driven by different
factors such as rising awareness for the cancer treatments, high demand for
safe and effective medications, technologies advancements, and increasing
prevalence of cancer.
Chronic
lymphocytic leukemia is a type of gradually developing leukemia that affects
the development of B lymphocytes (also known as B cells). On the other hand, B
cells are specialized white blood cells, which produce immunoglobulins (also
called antibodies) under normal conditions, and help to protect the human body
against infections and diseases. In patients with chronic lymphocytic leukemia,
lymphocytes undergo a malignant change and become leukemic cells.
Request to Get the
Sample Pages at:
Ono
Pharmaceutical and Bristol-Myers Squibb are in the process of developing Opdivo
for the treatment of chronic lymphocytic leukemia. Genentech is developing
Atezolizumab, also known as MPDL 3280A, for chronic lymphocytic leukemia
therapeutics, which is in Phase II stage. Atezolizumab is a monoclonal antibody
targeting programmed cell death-1 ligand 1 (PD-L1). PD-L1 plays an important
role in suppressing the immune system triggered by the cancer. PD-L1 acts by
reducing the proliferation of antigen-specific CD8+ T-cells and controlling the
accumulation of foreign antigen-specific T-cells.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=chronic-lymphocytic-leukemia-therapeutics-market
The chronic
lymphocytic leukemia is more prevalent in North America, making the
region to be the largest revenue contributor, globally. The U.S. contributed
the largest revenue to the North American market in year 2016, and it is
expected to remain the largest market across the globe, during the forecast
period.
Some of the
key players operating in the chronic lymphocytic leukemia therapeutics market
are GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Biogen
Inc., AbbVie, Inc., Teva Pharmaceuticals Limited, Gilead Sciences, Inc.,
Novartis AG, and Johnson & Johnson.
Restless Legs Syndrome Market Performance and Market Share, Sales Revenue and Major Manufacturers Performance, Gross Margin Analysis
Pramod KmrFebruary 10, 2019analysis, Growth, Outlook, Research, Restless Legs Syndrome Market, Restless Legs Syndrome Market Demand, Restless Legs Syndrome Market Share, Restless Legs Syndrome Market Size, Trends
1 comment
Restless
legs syndrome or RLS is a neurological disease. RLS is also called as
Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible
desire to move their feet. The continual movement of the legs leads to pain in
the limbs, which leads to the unusual sleep pattern of patients.
The exact
reason behind the restless
legs syndrome is not known precisely, however, it is believed the
disease is caused due to genetic factors or due to iron deficiency in the brain
or due to the disorders in dopaminergic balance.
The exact
treatment of this disease is not present till now. However the available drug
in the market helps in the indicative treatment of the disease. Some of the
drug in the restless legs syndrome market such as sulfonamide by safinamide by
Newron Pharmaceuticals reduces the symptoms by novel action such as potent,
reversible and selective inhibition of MAO-B, without disturbing the MAO-A and
dopamine uptake. This enhances the glutamate release and dopaminergic function
of the patients; it also reduces the dopamine degradation. One other drug:
SER-214 manufacture by Serina is used widely in the restless legs syndrome
treatment; it uses a water-soluble polymer poly (2-alkyloxazoline)-based drug
delivery technology this drug can be combined with the polymer and transported
to the patients.
Request to Get the
Sample Pages at:
Based on
the different product type the global restless legs syndrome market can be
broadly classified as Mirapex/Sifrol/Mirapexin, Neupro/Leganto, Requip, and
HORIZANT/Regnite. On the basis various disease type the global restless legs
syndrome market can be broadly bifurcated as etiology and pathogenesis, iron
deficiency, genetic factors, neurological disturbances and others. Based on the
mode of the therapy the global restless legs syndrome market can be broadly
segmented into two broad categories: pharmacological therapy and
non-pharmacological therapy.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=restless-legs-syndrome-market
Some of the
major players operating in the global restless legs syndrome market include,
GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG,
Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation,
Manhattan Pharmaceuticals, Boehringer Ingelheim GmbH, UCB SA.
Nuclear Medicine (Radiopharmaceuticals) Market by Overview, Growth Opportunities, Manufacturing Cost Structure Analysis, Outlook and Industry Insights Forecast to 2024
Pramod KmrFebruary 06, 2019Demand, Growth, Nuclear Medicine (Radiopharmaceuticals) Market, Outlook, Radiopharmaceuticals Market, Research Report, Share, Size, Trends
No comments
The global nuclear medicine/radiopharmaceuticalsmarket is growing significantly due to increasing prevalence of cancer and
cardiovascular diseases, and advances in nuclear medicine imaging procedures.
High demand of nuclear medicines in emerging economies and potential
radiopharmaceuticals in the pipeline create ample opportunities for the nuclear
medicine/radiopharmaceuticals market to grow at a considerable rate in the
coming years.
The advances in neurological applications and
development of new products by the companies are supporting to address the
demand for cost effectiveness of radiopharmaceuticals. Nuclear medicine imaging
procedures are non-invasive and can be used for the treatment of several
diseases, such as cancers, cardiovascular diseases, and neurological disorders.
Request to
Get the Sample Pages at:
The nuclear medicine/radiopharmaceuticals market
is segmented on the basis of type, application, and region. On the basis of
type, the nuclear medicine/radiopharmaceuticals market can be segmented as
diagnostics and therapeutics. The diagnostics segment leads the nuclear
medicine/radiopharmaceuticals market. The diagnostics segment can be further
categorized into single-photon emission computed tomography (SPECT) and
positron emission tomography (PET). SPECT segment will be leading the nuclear
medicine/radiopharmaceutical diagnostics market in the coming years due to its
wider availability and less cost. The therapeutics segment can be further
categorized into beta emitters, alpha emitters, and brachytherapy isotopes. The
beta emitters will be the leading segment in the global nuclear
medicine/radiopharmaceutical therapeutics market.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nuclear-medicine-market
Geographically, North America will be leading the
global nuclear medicine/radiopharmaceuticals market in the coming years due to
increasing prevalence of cancer, ready availability of radiopharmaceuticals,
popularity of nuclear medicine among physicians, and technological
advancements.
Asia-Pacific is the fastest growing region in the
global nuclear medicine/radiopharmaceuticals market. The major reasons for the
fastest growth in the region are increasing healthcare expenditure, and rising
awareness of radiopharmaceuticals among healthcare providers. Moreover, Japan
will be leading the nuclear medicine/radiopharmaceuticals market in
Asia-Pacific region in the coming years.
Some of the major players operating in the global
nuclear medicine/radiopharmaceuticals market are GE Healthcare, Bayer
Healthcare, Cardinal Health Inc., Eczacibasi-Monrol Nuclear Products, Bracco
Imaging S.p.A, Nordion Inc., Lantheus Medical Imaging Inc., Advanced
Accelerator Applications S.A, Mallinckrodt plc, and IBA Molecular Imaging.
Human Growth Hormone Market Share, Strategies, Emerging Technologies, Growth Rate Analysis, Trends and Forecast
Pramod KmrFebruary 04, 2019Emerging Technologies, Growth Rate Analysis, Human Growth Hormone Market Share, Research Report, Strategies, Trends
2 comments
The global human growth hormone market
is witnessing growth due to the presence of large pool of patients and
technological advancements. The increasing compliance for human growth hormone
drugs and massive unexplored market in the emerging economies, such as India
and China are creating opportunities for the growth of the global human growth
hormone market. The advanced research and development facilities, and new drug
developments by the key players are propelling the demand for improved and cost
effective human growth hormones; further fuelling the growth of the global
growth hormone market.
Some of the factors driving
the growth of the global human growth hormone market are increasing demand for
human growth hormone drugs, increasing incidences of human growth hormone
deficiency diseases, growing geriatric population, and technological
advancements, such as recombinant DNA technology for the development of human
growth hormone drugs. In addition, several major players are investing heavily
and collaborating among each other for the research and development of human
growth hormone drugs, which is fueling the growth of the global human growth
hormone market. However, stringent regulatory approvals, high cost of
treatment, and adverse effects associated with the usage of synthetic human
growth hormones are some of the factors restraining the growth of the global
human growth hormone market to some extent.
Request to Get the
Sample Pages at:
Geographically, North America leads the global
human growth hormone market, due to increasing proportion of aged population,
high incidences of turner syndrome, short bowel syndrome, human growth hormone
deficiency and Noonan syndrome. Moreover, the high demand of human growth
hormone drugs as performance enhancer and anti-aging drug in North America is
driving the growth of the human growth hormone market in the region.
Asia-Pacific is the fastest growing region in the global human growth hormone
market, which is driven by increasing healthcare expenditures and high
incidences of growth hormone deficiency disorders. Moreover, the human growth
hormone market is growing due to increasing disposable income and large
geriatric population in the emerging countries, such as India and China.
Make Enquiry
Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=human-growth-hormone-market
Some of the major players
operating in the global human growth hormone market are Pfizer Inc., F.
Hoffmann-La Roche AG, Novo Nordisk A/S, Merck KGaA, Eli Lilly and Company,
Novartis AG, and Teva Pharmaceutical Industries Ltd.
Global Endometrial Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2024
Pramod KmrFebruary 01, 2019Endometrial Cancer Therapeutics Market, Endometrial Cancer Therapeutics Market Size, Outlook, Research Report, Share, Trends
2 comments
Global endometrial cancer therapeutics market is expected to witness significant growth as there are
less number of approved drugs for treatment of endometrial cancer, leading to
an increased opportunity for the drug manufacturers. High prevalence of cancer
and rising demand for safe and effective medications can be attributed as the
major drivers of this market. The regulatory bodies such as USFDA and EMA are
supporting the growth of the global market by providing increased funding,
designations and grants for speeding up the drug development process.
Endometrial cancer is the malignancy that develops in the
layers of the cells that forms endometrium, lining of uterus. The precise cause
of endometrial cancer is still unknown but it is assumed that estrogen may be
involved in developing endometrial cancer, as estrogen helps in the formation
of the endometrial lining. Obesity, polycystic ovary syndrome, infrequent
periods and history of endometrial polyps can increase the risk of endometrial
cancer. Women with diabetes, high blood pressure or breast cancer are at a
greater risk of having endometrial cancer. Abnormal vaginal bleeding, bleeding
between periods or after menopause, lower abdominal cramps or clear vaginal
discharge after menopause are some of the main symptoms of endometrial cancer.
High prevalence and recurrence of endometrial cancer
after treatment with chemotherapy are the major driving factors driving the
endometrial cancer therapeutic market. Growing prevalence of obesity in
women aged 50 years or above is also contributing in the growth of the
endometrial cancer therapeutics market globally. Apart from this, safety
concerns after chemotherapy, hormone therapy and radiation therapy restrict the
medications for the treatment of endometrial cancer.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=endometrial-cancer-treatment-market
Geographically,
North America is expected to be the largest market for endometrial cancer
therapeutics treatment, owing to the large number of research and development
activities ad high healthcare expenditure. Europe is expected to hold the
second largest share in the global market owing to growing product availability
in the region.
Some of the
key players operating in the global endometrial cancer therapeutics market are
AstraZeneca Plc., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc. and
R-Pharm-US LLC.
Medical Marijuana Market Opportunities by Types, Demand, Top Manufactures and Application in Grooming Regions
Pramod KmrJanuary 30, 2019Medical Marijuana Market, Medical Marijuana Market Demand, Medical Marijuana Market Growth, Medical Marijuana Market Share, Medical Marijuana Market Size, Outlook, Trends
18 comments
The global
medical marijuana market is expected to witness considerable growth during the
forecast period on account of the rise in the number of countries legalizing
the consumption of the drug for medicinal purposes and its potential
application in the treatment of several chronic diseases. Increasing awareness
among healthcare providers and individuals regarding the benefits of medicinal
marijuana will also support the market growth in the future. Moreover, growing
investments (by both private and public organizations) in research associated
with the use of marijuana for medical purposes are expected to continue driving
the market growth.
On the
basis of application, the medical marijuana market is categorized into chronic
pain, arthritis, migraine, cancer, and others. Among these, chronic pain is the
largest application area of medical marijuana and is expected to continue
leading the market during the coming years. This can be attributed to the
increasing prevalence of chronic diseases and rising awareness among patients
and healthcare providers regarding the potential benefits of using marijuana
for relieving chronic pain.
Request to Get the
Sample Pages at:
Globally, North
America was the largest revenue generator in the medical marijuana market in
2017, because of high investments in research and development activities to
investigate the potential medical applications of cannabinoids. Moreover,
Canada and some states of the U.S. are planning to legalize the usage of
marijuana for medical as well as recreational purposes. For instance, by
October 2018, Canada plans to legalize the drug use by adults. As per the
current medical regime associated with cannabis, patients are allowed to access
cannabis under the authorization of their healthcare providers.
Thus, government initiatives to spread awareness about the medical application of marijuana and legalize its usage are expected to contribute to the market growth in the near future.
Thus, government initiatives to spread awareness about the medical application of marijuana and legalize its usage are expected to contribute to the market growth in the near future.
Some of the
major factors contributing to the growth of the medical marijuana industry are
the increasing prevalence of chronic diseases, growing investments by public
and private organizations to conduct research focusing on the medical applications
of marijuana, and rising awareness among healthcare providers toward the usage
of the drug.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=medical-marijuana-market
Several
research projects have been funded by the National Institute of Health (NIH)
and the National Institute on Drug Abuse (NIDA) to explore the possible
benefits of marijuana in different medical conditions. Furthermore, increasing
consumption of cannabinoid-based drugs approved for certain disorders is
promoting the market growth. For instance, nabiximols (Sativex), a mouth spray
containing two cannabinoids of marijuana, that is, tetrahydrocannabinol (THC)
and cannabidiol (CBD), is used for treating muscle control problems caused by
multiple sclerosis. Nabiximols is approved in the U.K., Canada, and several European
countries, and studies are being conducted for the drug approval in the U.S. as
well.
Players,
through the acquisition of other similar companies, are strengthening their
position in the medical
marijuana market. For instance, in October 2018, Wuhan General
Group [China] Inc. (Wuhan) announced that it signed a letter of intent to
acquire MJ MedTech Inc. (MedTech), a manufacturer of medical marijuana and
cannabidiol (CBD) products. Through this acquisition, Wuhan expects to gain
from MedTech’s insights, market value, and advanced technology to establish its
presence in the U.S., Canadian, and European markets and strengthen its
position in the medical CBD product business.
Some of the
other key players in the medical marijuana industry are Canopy Growth
Corporation, Aurora Cannabis Inc., Medical Marijuana Inc., GW Pharmaceuticals
PLC, Aphria Inc., CanniMed Ltd., Tilray Inc., and Emerald Health Therapeutics
Inc.























